Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma

Author:

George Saby1,Rini Brian I.2,Hammers Hans J.3

Affiliation:

1. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York

2. Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

3. Department of Internal Medicine, UT Southwestern, Kidney Cancer Program, Dallas, Texas

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference48 articles.

1. Resistance to targeted therapy in renal-cell carcinoma.;Rini;Lancet Oncol,2009

2. Immunotherapy for renal cell carcinoma.;Itsumi;Clin Dev Immunol,2010

3. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma.;Noessner;Oncoimmunology,2012

4. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.;Fisher;Cancer J Sci Am,2000

5. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.;Fyfe;J Clin Oncol,1995

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3